Healthcare stocks were mixed pre-bell Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.1% and the iShares Biotechnology ETF (IBB) 0.5% lower.
Ascendis Pharma (ASND) will regain exclusive rights to certain drug treatments for metabolic and cardiovascular diseases, including obesity, having terminated a 2024 collaboration deal with Novo Nordisk (NVO), the company said. Shares of Ascendis Pharma were down less than 3% premarket.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.